Cell Therapy Technologies Market

The global cell therapy technologies market is anticipated to reach USD 6.80 billion in 2029 from USD 4.03 billion in 2024, with a significant CAGR of 11.0%. Major growth drivers of the market are an increase in funding and investments in cell therapy, advancements in gene editing technologies, technologically advanced automated cell processing systems, and regulatory support for accelerating therapies.

The market for cell therapy technologies market is consolidated. Prominent players in the cell therapy technologies market are Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc.  (US), Avantor, Inc. (US), Bio-Techne (US), Avantor, Inc. (US), Fresenius SE & Co KGAA (Germany), BD (US), Corning Incorporated (US) and among others.

To know about the assumptions considered for the study download the pdf brochure

Danaher Corporation is among the leading companies in cell therapy technologies. The company has evolved as one of the greatest companies in the biotechnology market due to its acquisition of Pall Corporation for USD 13.8 billion in August 2015 and Biopharma business (Cytiva) of GE Healthcare for USD 21 billion in March 2020. The company is aggressive toward strategic alliances, mergers, and new product development. For example, Cytiva recently launched three new cell lines under the brand ELEVECTA in April 2024, with which to face the challenges and growing demand for viral vector manufacturing.

Merck KGaA is also one of the leading firm in cell therapy technologies market. The company operates in the cell therapy technologies market through its life science business segment. The company’s leading position is attributable to its diversified product portfolio, strong geographic presence, and adoption of organic and inorganic growth strategies. For instance, in August 2024, Merck KGaA acquired Mirus Bio (US) to advance Merck’s integrated offering for viral vector manufacturing.

Thermo Fisher Scientific Inc. is one of the leaders in cell therapy technologies. The company has a broad portfolio of products. Among the major strengths of the diversified product offerings include strong geographic presence, organic and inorganic growth strategies, and commitment towards launching new solutions in the market which further helps it to hold its ground. For example, in June 2024, Thermo Fisher launched the Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators to offer innovative features compatible to help gear toward emerging automated cell therapy production processes.

Related Reports:

Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Vessels, Single-Use Equipment), Process (Cell Processing, Preservation, Distribution, QC), Cell type (T-Cells, Stem cells), Application (Cancer, CVD), End user - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]